08:48 AM EDT, 06/14/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that long-term data from an early-to-mid stage study of its drug, Talvey, to treat certain patients with multiple myeloma showed high overall response rates and durable responses, irrespective of prior T-cell redirection therapy.

The company said the study showed that patients treated with the drug had a 67.1% overall survival rate at 24 weeks.

"It is encouraging to see no notable increases in treatment-related discontinuations with this longer follow-up across cohorts," said Leo Rasche, attending physician on the myeloma service, University Hospital of Wurzburg.

Price: 145.34, Change: -0.11, Percent Change: -0.08